Pyxis Oncology (PYXS) Non-Current Assets (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Non-Current Assets data on file, last reported at $19.4 million in Q4 2025.

• Non-Current Assets for Q4 2025 came in at $19.4 million, down 21.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $89.2 million (down 46.39% YoY), and the FY2025 annual result was $19.4 million, down 21.53% from the prior year.
• Non-Current Assets eased to $19.4 million in Q4 2025 per PYXS's latest filing, from $22.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $49.1 million in Q4 2023 and troughed at $1.3 million in Q4 2021.
• A 5-year average of $26.4 million and a median of $24.4 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 1743.56% in 2023, then plunged 51.49% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $1.3 million in 2021, then jumped by 1737.31% to $24.8 million in 2022, then surged by 98.34% to $49.1 million in 2023, then plunged by 49.63% to $24.7 million in 2024, then decreased by 21.53% to $19.4 million in 2025.
• Business Quant data shows PYXS's Non-Current Assets at $19.4 million in Q4 2025, $22.5 million in Q3 2025, and $23.3 million in Q2 2025.